A Parallel-group Treatment, Phase 2a, Multicenter, Randomized, Double-blind, Placebo-controlled Umbrella Study to Evaluate the Efficacy and Safety of Frexalimab, SAR442970, and Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis (FSGS) or Minimal Change Disease (MCD)
Latest Information Update: 17 Jun 2025
At a glance
- Drugs Frexalimab (Primary) ; Rilzabrutinib (Primary) ; SAR 442970 (Primary)
- Indications Lipoid nephrosis
- Focus Therapeutic Use
- Acronyms RESULT
- Sponsors Sanofi
Most Recent Events
- 10 Oct 2024 Status changed from not yet recruiting to recruiting.
- 22 Jul 2024 New trial record